Drug Trial Radar · NCT00360243
6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA
Last checked: Nov 20, 2026Latest source record: Jun 27, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,385
Actual
Start
Jul 2006
Primary completion
Apr 2008
Study completion Apr 2008
Sponsor
- Lead sponsor
- Sprout Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 4, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meet standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.
Conditions
- Sexual Dysfunctions, Psychological
Interventions
flibanserinDrug
Experimental: flibanserin 25 mg b.i.d
flibanserinDrug
Experimental: flibanserin 50mg qhs
flibanserinDrug
Experimental: flibanserin 50mg b.i.d.
placeboDrug
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline to 24 Weeks in the Frequency of Satisfying Sexual Events as Measured by the eDiary.Time frame: 24 weeks
- Change From Baseline to 24 Weeks in Responses to the eDiary Daily Desire Question.Time frame: baseline to 24 weeks
Locations
81 sites in 1 country. Site status is shown where the registry gives one.
511.70.01068 Boehringer Ingelheim Investigational Site
Huntsville, Alabama
511.70.01040 Boehringer Ingelheim Investigational Site
Mobile, Alabama
511.70.01041 Boehringer Ingelheim Investigational Site
Tucson, Arizona
511.70.01003 Boehringer Ingelheim Investigational Site
Jonesboro, Arkansas
511.70.01070 Boehringer Ingelheim Investigational Site
Carmichael, California
511.70.01026 Boehringer Ingelheim Investigational Site
Redding, California
511.70.01015 Boehringer Ingelheim Investigational Site
San Diego, California
511.70.01014 Boehringer Ingelheim Investigational Site
Stanford, California
511.70.01017 Boehringer Ingelheim Investigational Site
Tarzana, California
511.70.01072 Boehringer Ingelheim Investigational Site
Torrance, California
511.70.01078 Boehringer Ingelheim Investigational Site
Vista, California
511.70.01066 Boehringer Ingelheim Investigational Site
Walnut Creek, California
511.70.01064 Boehringer Ingelheim Investigational Site
Denver, Colorado
511.70.01001 Boehringer Ingelheim Investigational Site
Wheat Ridge, Colorado
511.70.01050 Boehringer Ingelheim Investigational Site
Farmington, Connecticut
511.70.01006 Boehringer Ingelheim Investigational Site
Hartford, Connecticut
511.70.01055 Boehringer Ingelheim Investigational Site
New London, Connecticut
511.70.01024 Boehringer Ingelheim Investigational Site
Aventura, Florida
511.70.01056 Boehringer Ingelheim Investigational Site
Daytona Beach, Florida
511.70.01090 Boehringer Ingelheim Investigational Site
Fort Lauderdale, Florida
511.70.01027 Boehringer Ingelheim Investigational Site
Gainesville, Florida
511.70.01062 Boehringer Ingelheim Investigational Site
New Port Richey, Florida
511.70.01043 Boehringer Ingelheim Investigational Site
Orlando, Florida
511.70.01084 Boehringer Ingelheim Investigational Site
Pembroke Pines, Florida
511.70.01048 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida
511.70.01042 Boehringer Ingelheim Investigational Site
Stuart, Florida
511.70.01063 Boehringer Ingelheim Investigational Site
Tampa, Florida
511.70.01085 Boehringer Ingelheim Investigational Site
Tampa, Florida
511.70.01086 Boehringer Ingelheim Investigational Site
West Palm Beach, Florida
511.70.01022 Boehringer Ingelheim Investigational Site
Atlanta, Georgia
511.70.01057 Boehringer Ingelheim Investigational Site
Atlanta, Georgia
511.70.01087 Boehringer Ingelheim Investigational Site
Atlanta, Georgia
511.70.01052 Boehringer Ingelheim Investigational Site
Roswell, Georgia
511.70.01060 Boehringer Ingelheim Investigational Site
Champaign, Illinois
511.70.01058 Boehringer Ingelheim Investigational Site
Chicago, Illinois
511.70.01032 Boehringer Ingelheim Investigational Site
Indianapolis, Indiana
511.70.01018 Boehringer Ingelheim Investigational Site
Lexington, Kentucky
511.70.01007 Boehringer Ingelheim Investigational Site
Baton Rouge, Louisiana
511.70.01047 Boehringer Ingelheim Investigational Site
New Orleans, Louisiana
511.70.01079 Boehringer Ingelheim Investigational Site
New Orleans, Louisiana
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.